Systemic Mastocytosis

Masitinib in Patients With Mild Alzheimer's Disease

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Masitinib Plus Gemcitabine in Pancreatic Cancer

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Masitinib in Refractory Active Rheumatoid Arthritis

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis